eFFECTOR Therapeutics

Historical price data

eFFECTOR Therapeutics was founded to exploit dysregulated protein synthesis as a new therapeutic strategy in oncology. Its mission was to develop selective translation regulator inhibitors (STRIs) targeting the eIF4F complex, advancing two primary candidates, zotatifin and tomivosertib, into clinical trials for various solid tumors. The company's strategy was to move beyond targeting single mutations to disrupt the broader 'translationome' driving tumor growth and therapy resistance. Despite achieving key clinical milestones and raising significant capital as a public entity, eFFECTOR ultimately failed to secure further funding or partnerships, leading to its dissolution.

Platform focused on selective translation regulator inhibitors (STRIs) targeting the eukaryotic initiation factor 4F (eIF4F) complex to disrupt the synthesis of oncogenic and immune-evasion proteins in cancer cells.

eFFECTOR was a pioneer in direct translation inhibition, facing limited direct late-stage competition but bearing the full burden of clinical proof-of-concept for the drug class. Indirect competition came from established pathway inhibitors (e.g., mTOR). The company's dissolution may increase perceived risk for other entities in this space.